

QIBA PET-Amyloid Biomarker Committee (BC) Call

8 February 2019 at 9:00 AM CT

Call Summary

In attendance:

Anne Smith, PhD (Co-Chair)

Tammie Benzinger, MD, PhD

Adriaan Lammertsma, PhD

Nancy Obuchowski, PhD

Jean-Luc Vanderheyden, PhD

RSNA

Joe Koudelik

Julie Lisiecki

Moderator: Dr. Smith

Notes provided by Dr. Smith and supplemented by RSNA Staff

Next targets:

- The primary goal is achieving Profile technical confirmation by 4Q2019
- In order to achieve this, the conformance process must be finalized
- Dr. Kinahan's amyloid DRO work will be used for conformance testing
 - Vendor reps are ready to do testing; they include MIMVista, Siemens, and others
 - Dr. Smith and Ms. Matthews will reach out directly to Dr. Kinahan to ensure next steps are completed for DRO evaluation

Questionnaire for Technical Confirmation (Feasibility Testing) Preparation:

- Ms. Matthews has been working on the draft questionnaire for volunteer sites
- [SurveyMonkey](#) will be the questionnaire platform
- The team plans to get the questionnaire to sites by 2Q2019
- Dr. Lammertsma volunteered to help Ms. Matthews develop the questionnaire, and will contact her directly
- Once the initial draft is complete, Dr. Lammertsma will get feedback from European sites/groups

Next Profile Ideas for the BC:

- Tau is considered as "Wild West," as there is no regulatory approval and there is still off-target binding, etc.
- Although interest exists, consensus was that it was too early to develop a Tau Profile
- The BC is considering adding MR/PET to the next Profile version since attenuation correction for brain studies has improved

QIBA Nuclear Medicine Schedule:

The next scheduled QIBA calls will be as follows at **9 am CT** unless otherwise noted:

2/12/2019	SPECT BC: TC ^{99m} @ 2pm CT
2/15/2019	I-123 BC – TBD by co-chairs
2/22/2019	Hold for NM Coordinating Committee
3/1/2019	FDG-PET BC
3/8/2019	PET Amyloid BC
3/12/2019	SPECT BC: TC ^{99m} @ 2pm CT
3/15/2019	I-123 BC - TBD by co-chairs
3/22/2019	NM Leadership - TBD